LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,417,657
تعداد دریافت فایل اصل مقاله11,295,841
Peer-Firozjaei, Milad, Tajik-Mansoury, Mohammad Ali, Ghorbani, Raheb, Mazinani, Mahdi. (1400). Evaluation of Dosimetric Parameters for Tumor Therapy with 177Lu and 90Y Radionuclides in Gate Monte Carlo Code. سامانه مدیریت نشریات علمی, 11(3), 263-270. doi: 10.31661/jbpe.v0i0.2101-1256
Milad Peer-Firozjaei; Mohammad Ali Tajik-Mansoury; Raheb Ghorbani; Mahdi Mazinani. "Evaluation of Dosimetric Parameters for Tumor Therapy with 177Lu and 90Y Radionuclides in Gate Monte Carlo Code". سامانه مدیریت نشریات علمی, 11, 3, 1400, 263-270. doi: 10.31661/jbpe.v0i0.2101-1256
Peer-Firozjaei, Milad, Tajik-Mansoury, Mohammad Ali, Ghorbani, Raheb, Mazinani, Mahdi. (1400). 'Evaluation of Dosimetric Parameters for Tumor Therapy with 177Lu and 90Y Radionuclides in Gate Monte Carlo Code', سامانه مدیریت نشریات علمی, 11(3), pp. 263-270. doi: 10.31661/jbpe.v0i0.2101-1256
Peer-Firozjaei, Milad, Tajik-Mansoury, Mohammad Ali, Ghorbani, Raheb, Mazinani, Mahdi. Evaluation of Dosimetric Parameters for Tumor Therapy with 177Lu and 90Y Radionuclides in Gate Monte Carlo Code. سامانه مدیریت نشریات علمی, 1400; 11(3): 263-270. doi: 10.31661/jbpe.v0i0.2101-1256

Evaluation of Dosimetric Parameters for Tumor Therapy with 177Lu and 90Y Radionuclides in Gate Monte Carlo Code

Journal of Biomedical Physics and Engineering
مقاله 1، دوره 11، شماره 3، شهریور 2021، صفحه 263-270    اصل مقاله (927.3 K)
نوع مقاله: Original Research
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.2101-1256
نویسندگان
Milad Peer-Firozjaei1؛ Mohammad Ali Tajik-Mansoury* 2؛ Raheb Ghorbani3، 4؛ Mahdi Mazinani1
1MSc, Department of Medical Physics, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
2PhD, Department of Medical Physics, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
3PhD, Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran
4PhD, Department of Epidemiology and Biostatistics, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
چکیده
Background: 90Y and 177Lu are two well-known radionuclides used in radionuclide therapy to treat neuroendocrine tumors.
Objective: This current study aims to evaluate, compare and optimize tumor therapy with 90Y and 177Lu for different volumes of the tumor using the criterion of self-absorbed dose, cross-absorbed dose, absorbed dose profile, absorbed dose uniformity, and dose-volume histogram (DVH) curve using Gate Monte Carlo simulation code.
Material and Methods: In our analytical study, Gate Monte Carlo simulation code has been used to model tumors and simulate particle transport. Spherical tumors were modeled from radius 0.5 to 20 mm. Tumors were uniformly designed from water (soft tissue reagent). The full energy spectrum of each radionuclide of 177Lu and 90Y was used in the total volume of tumors with isotropic radiation, homogeneously. Self-absorbed dose, cross-absorbed dose, absorbed dose profile, absorbed dose uniformity, and DVH curve parameters were evaluated.
Results: The absorbed dose for 90Y is higher than 177Lu in all tumors (p-value <5%). The uniformity of the absorbed dose for 177Lu is much greater than 90Y. As the tumor size increases, the DVH graph improves for 90Y.
Conclusion: Based on self-absorbed dose, cross-absorbed dose, absorbed dose uniformity, and DVH diagram, 177Lu and 90Y are appropriate for smaller and larger tumors, respectively. Next, we can evaluate the appropriate cocktail of these radionuclides, in terms of the type of composition, for the treatment of tumors with a specific size.
کلیدواژه‌ها
Radionuclide Tumor Therapy؛ Gate Monte Carlo؛ Dosimetry؛ DVH؛ Lutetium-177؛ Yttrium-90
سایر فایل های مرتبط با مقاله
مراجع
  1. Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clinical applications of newer radionuclide therapies. European Journal of Cancer. 2006;42(8):994-1003. doi: 10.1016/j.ejca.2005.12.020. PubMed PMID: 16564689.
  2. Saha GB. Physics and radiobiology of nuclear medicine. Springer Science & Business Media; 2012. doi: 10.1007/978-0-387-36281-6.
  3. Stigbrand T, Carlsson J, Adams GP, editors. Targeted radionuclide tumor therapy: Biological aspects. New York: Springer; 2008. doi: 10.1007/978-1-4020-8696-0.
  4. Zavgorodni SF. A model for dose estimation in therapy of liver with intraarterial microspheres. Phys Med Biol. 1996;41(11):2463-80. doi: 10.1088/0031-9155/41/11/016. PubMed PMID: 8938039.
  5. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol. 1996;41(10):1905-14. doi: 10.1088/0031-9155/41/10/004. PubMed PMID: 8912370.
  6. Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K. MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151-62. doi: 10.2967/jnumed.115.159012. PubMed PMID: 26471692.
  7. Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90 Y-DOTATATE and tandem 90 Y/177 Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38(10):1788-97. doi: 10.1007/s00259-011-1833-x. PubMed PMID: 21553086. PubMed PMCID: PMC3168754.
  8. Huizing DMV, Verheij M, Stokkel MPM. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI Res. 2018;8(1):1-11. doi: 10.1186/s13550-018-0443-z. PubMed PMID: 30159614. PubMed PMCID: PMC6115319.
  9. Enger SA, Hartman T, Carlsson J, Lundqvist H. Cross-fire doses from β-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics. Phys Med Biol. 2008;53(7):1909-20. doi: 10.1088/0031-9155/53/7/007. PubMed PMID: 18364546.
  10. Erdi AK, Erdi YE, Yorke ED, Wessels BW. Treatment planning for radio-immunotherapy. Phys Med Biol. 1996;41(10):2009-26. doi: 10.1088/0031-9155/41/10/011. PubMed PMID: 8912377.
  11. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986;27(9):1490-7. PubMed PMID: 3528417.
  12. Spaic R, Ilic R, Dragovic M, Petrovic B. Generation of dose-volume histograms using Monte Carlo simulations on a multicellular model in radionuclide therapy. Cancer Biother Radiopharm. 2005;20(3):320-4. doi: 10.1089/cbr.2005.20.320. PubMed PMID: 15989478.
  13. O’Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36(10):1902-9. PubMed PMID: 7562062.
  14. Wong FC. MIRD: radionuclide data and decay schemes. JNM. 2009;50(12):2091. doi: 10.2967/jnumed.109.069948.
  15. Khan FM, Gibbons JP. Khan’s the physics of radiation therapy. Lippincott Williams & Wilkins; 2014.
  16. De Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):13S-7S. PubMed PMID: 15653647.
  17. Navalkissoor S, Flux G, Bomanji J. Molecular radiotheranostics for neuroendocrine tumours. Clin Med (Lond). 2017;17(5):462-8. doi: 10.7861/clinmedicine.17-5-462. PubMed PMID: 28974600. PubMed PMCID: PMC6301943.
آمار
تعداد مشاهده مقاله: 1,794
تعداد دریافت فایل اصل مقاله: 443


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب